



Gabriella Agnese

Senior Associate

Sydney
+61.2.9513.2485

Gabriella.Agnese@klgates.com

OVERVIEW

Gabriella Agnese is a senior associate in our Commercial Litigation & Dispute Resolution team in Sydney. She has worked for insurers and commercial clients on a range of litigated and unlitigated disputes. Her experience includes acting for a variety of clients including solicitors, accountants, engineers and architects in professional negligence claims. She has also acted in a number of litigated matters brought against directors and officers and in disputes with the ATO. Gabriella has significant experience acting for both insurers and insureds in relation to policy interpretation and disputes.

ACHIEVEMENTS

- Listed by *Best Lawyers in Australia: Ones to Watch*™ for Insurance Law and Litigation, 2023-2024
- Recognised by *K&L Gates* in the Women's Achievements Awards for Client Service, 2023

EDUCATION

- Graduate Diploma in Legal Practice, College of Law, 2016
- LL.B., Macquarie University, 2015 (*Hons*)
- B.Com, Macquarie University, 2015 (*Hons*)
- International Law Program, University of Vienna, 2014

ADMISSIONS

- High Court of Australia
- Supreme Court of New South Wales

AREAS OF FOCUS

- Commercial Disputes

REPRESENTATIVE EXPERIENCE

- Defended proceedings brought by the creditors of the Forge Group: *Swiss Re International & Anor v Simpson & Ors* [2018] NSWSC 233.
- Appealed a sequestration order made in ASIC's favour: *Hutchings v ASIC* [2017] FCA 858.
- Acted in relation to an ASIC prosecution of the former directors and officers of MFS Investment Management Pty Ltd: *King & Ors v ASIC* [2018] QCA 352.
- Acted in a number of defamation matters including: *Hanson-Young v Leyonhjelm (No 4)* [2019] FCA 1981; *Herron v HarperCollins Publishers Australia Pty Ltd* [2018] FCA 1495; *Kidu v Fifer & Ors* [2016] NSWSC 488.
- Advised Insurers in relation to coverage of a class action against a large financial advisory company under an Investment Management Policy.
- Advised Insurers of a pharmaceutical and biotechnology company in relation to a business interruption claim arising from the delay of a medical research trial.
- Acted for a large industry body in a negligent misstatement claim brought against the Commonwealth government.